50% off Premium Yearly

NYSE:SYK
This summary was created by AI, based on 6 opinions in the last 12 months.
Stryker Corp. (SYK) faces challenges, including the recent cybersecurity incident affecting production and overall weakness in the health sector, but maintains a strong reputation as a leader in medical devices, particularly in orthopedics. Analysts highlight the attractiveness of the stock’s valuation, with expectations of significant earnings growth, forecasting $15 EPS by 2027 at a 20x PE ratio, driven by a 10% topline growth amidst an aging population. With a consistent market share gain from competitors like JNJ and ZBH, Stryker’s focus on robot-assisted surgeries in orthopedics is expected to double in growth over five years. Despite the current struggles in medtech, experts believe holding onto the stock could be beneficial in the long term, given its strong fundamentals and solid track record of acquisitions.
Medtronic vs. Stryker Both make medical devices, and have been impacted by COVID, because operations have been delayed. But now those ops are coming back. She owns JNJ instead, which includes a medical devices division. Unless there's a sharp uptick in the virus that shuts down hospitals again, demand for medical devices should rise and should even ramp in the near future.
Likes it. He hasn't bought it, because he isn't sure which stock to own in this sector. Abbott and Boston Scientific are better choices, he thinks, with more upside potential given product innovation.
A great medical equipment company. Over time, they've consolidated and grown. Demographic trends are on his side. But he owns Abbott instead; you can't own everything. Wait for more of a pullback to buy. If the PE falls to the low-$20s, step in.
A manufacturer of medical and surgical devices. The company has had positive sales growth for over 40 years. They do a great job at identifying areas where they are weak, finding a way to fill that gap and executing the strategy quickly. There is not much exposure they hold in China -- fortuitous right now. Yield 1.03% (Analysts’ price target is $232.92)